Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate CG Oncology, Inc. before investing.

In this article, we go over a few key elements for understanding CG Oncology, Inc.’s stock price such as:

• CG Oncology, Inc.’s current stock price and volume
• Why CG Oncology, Inc.’s stock price changed recently
• Upgrades and downgrades for CGON from analysts
• CGON’s stock price momentum as measured by its relative strength

About CG Oncology, Inc. (CGON)

Before we jump into CG Oncology, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003, which is in phase 3 clinical trial for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 that is in phase 2 clinical trial to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy that is in phase 3 clinical trial for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008, which is in phase 2 clinical trial for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.

Want to learn more about CG Oncology, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about CG Oncology, Inc..

CG Oncology, Inc.’s Stock Price as of Market Close

As of May 02, 2025, 12:46 PM, CST, CG Oncology, Inc.’s stock price was $29.480.

CG Oncology, Inc. is up 6.27% from its previous closing price of $27.740.

During the last market session, CG Oncology, Inc.’s stock traded between $28.360 and $29.640. Currently, there are approximately 69.05 million shares outstanding for CG Oncology, Inc..

CG Oncology, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

CG Oncology, Inc. Stock Price History

CG Oncology, Inc.’s (CGON) price is currently up 9.43% so far this month.

During the month of May, CG Oncology, Inc.’s stock price has reached a high of $29.640 and a low of $26.040.

Over the last year, CG Oncology, Inc. has hit prices as high as $46.990 and as low as $14.800. Year to date, CG Oncology, Inc.’s stock is up 2.79%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused CG Oncology, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 01, 2025, there were 2 analysts who downgraded CG Oncology, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate CG Oncology, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on CG Oncology, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

CG Oncology, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about CG Oncology, Inc. (CGON) by visiting AAII Stock Evaluator.

Relative Price Strength of CG Oncology, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 01, 2025, CG Oncology, Inc. has a weighted four-quarter relative price strength of -8.50%, which translates to a Momentum Score of 31 and is considered to be Weak.

Want to learn more about how CG Oncology, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

CG Oncology, Inc. Stock Price: Bottom Line

As of May 2, 2025, CG Oncology, Inc.’s stock price is $29.480, which is up 6.27% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like CG Oncology, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.